<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2082">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05134064</url>
  </required_header>
  <id_info>
    <org_study_id>2018-104</org_study_id>
    <nct_id>NCT05134064</nct_id>
  </id_info>
  <brief_title>68Ga-PSMA PET/CT Imaging in Assessment of Prostate Cancer</brief_title>
  <official_title>68Ga-PSMA PET/CT Imaging in Assessment of PCa: Feasibility of Delayed Acquisition on Total-body PET/CT Scanner?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dual-time point 68Ga-PSMA PET/CT could increase the lesion detection in PCa patients, it&#xD;
      remains difficult to perform in clinical practice. The possibility of one-time point&#xD;
      68Ga-PSMA PET/CT imaging could be achieved using a total-body PET/CT.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Actual">August 31, 2021</completion_date>
  <primary_completion_date type="Actual">July 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Only one-time point scan is possible for PSMA PET/CT</measure>
    <time_frame>8 months</time_frame>
    <description>By the use of total- body PET/CT scanner, the imaging quality between the 1 h p.i. and 3 h p.i. imaging acquisition are compared. And the different lesion detection rates at 3 h p.i. and 1 h p.i. are also discussed. The uptake value differences of all lesions are compared.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">66</enrollment>
  <condition>PET/CT</condition>
  <condition>Prostate Specific Membrane Antigen</condition>
  <condition>IMAGE</condition>
  <arm_group>
    <arm_group_label>PCa patients underwent 1 h p.i. PSMA PET/CT imaging and 3 h p.i. PSMA imaging</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>total-body PET/CT</intervention_name>
    <description>PCa patients who underwent PSMA PET/CT in our clinical center received two-time points scans at 1 h p.i. and 3 h p.i. on a total-body PET/CT scanner.</description>
    <arm_group_label>PCa patients underwent 1 h p.i. PSMA PET/CT imaging and 3 h p.i. PSMA imaging</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The prospective study consisted of 56 patients for 68Ga-PSMA-11 total-body PET/CT&#xD;
        examination between December 2020 and July 2021.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  primary staging of pathology-confirmed PCa or evidence of BCR with PSA value &gt; 0.2&#xD;
             ng/ml&#xD;
&#xD;
          -  positive 68Ga-PSMA findings&#xD;
&#xD;
          -  both standard and delayed scans were performed on the total-body PET/CT&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  only one scan was performed&#xD;
&#xD;
          -  negative PSMA results&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai jiaotong University School of Medicine, Renji Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 3, 2021</study_first_submitted>
  <study_first_submitted_qc>November 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>RenJi Hospital</investigator_affiliation>
    <investigator_full_name>Yumei Chen</investigator_full_name>
    <investigator_title>deputy head of the department of nuclear medicine</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

